Atlas Trials

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT06425991 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06425991
Sponsor
Janssen Research & Development, LLC
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2024-06-07
Primary completion
2025-06-03
Enrollment
108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.